An Analysis of Genomic and Molecular Profiles of Lung Cancer for the Prediction of Response to Therapy and Clinical Outcomes
This is a retrospective study. no treatment or invasive procedures are involved. Patients with a tissue diagnosis of lung cancer from 1998 to the present (the limits of the assay) will be identified through tumor registries and from iRB 122010-041. available pathology specimens will be identified and reviewed for adequacy. if sufficient tissue is available, unstained slides will be prepared. Genomic microarrays will be performed. Depending on the results, confirmatory studies (potentially including PCR, immunohistochemistry, and proteomics) will be undertaken.
Separately and simultaneously, we will perform a medical records review of these patients to compile demographic, diagnostic, therapeutic, and outcome data. We plan to collect the following variables: name, medical record number, social security number, date of birth, gender, race/ethnicity, smoking status, occupational exposures, family history, date of diagnosis, stage and location(s) of cancer, histologic subtype, site(s) of biopsy, dates and types of surgery/radiation therapy/chemotherapy, response to therapy, vital status, date of death, progression-free survival and overall survival.
Data will be analyzed statistically. Microarray data will be used to characterize and group tissue specimens. Corresponding clinical data (eg, response and survival rates) will be compared among groups.
Subjects with a tissue diagnosis of lung cancer from 1/1/1998 to the present who have sufficient tissue available in the UTSW pathology department for the planned molecular analyses.